• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Life Sciences
  • Investments
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

Sequel twiist AID System to Integrate with Senseonics Eversense 365 One-Year CGM

by Jasmine Pennic 04/30/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Sequel Med Tech, LLC, known for its innovative insulin delivery technology, and Senseonics Holdings, Inc., developer of long-term implantable continuous glucose monitoring (CGM) systems, announced a significant commercial development agreement. 

– The collaboration will integrate Sequel’s twiist™ Automated Insulin Delivery (AID) System, powered by Tidepool, with Senseonics’ Eversense® 365 CGM system.

This partnership marks a notable advancement in diabetes management, as the twiist™ AID System is set to become the first automated insulin delivery system compatible with the Senseonics Eversense 365. The Eversense 365 stands out as the world’s only CGM system featuring a sensor designed to last for a full year, offering unprecedented longevity for users. The integration aims to provide people living with type 1 diabetes a new level of flexibility and personalization in managing their condition.

This agreement expands the choices available to users of the twiist™ system. Once integrated, individuals with type 1 diabetes using twiist will have the flexibility to select between two compatible CGM partners: the Senseonics Eversense 365 or Abbott’s FreeStyle Libre 3 Plus sensor, allowing them to choose the option that best suits their individual needs.

FDA Clearance

The path for this integration was paved in September 2024 when the Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system, specifically allowing its use within AID systems. Driven by a shared commitment to simplifying diabetes management, Senseonics and Sequel have already commenced the integration work.

The twiist™ AID System itself, cleared for use in individuals aged six and older with type 1 diabetes, features unique technology that directly measures the volume of insulin delivered with each micro-dose. Its algorithm, based on the community-driven Tidepool Loop, automatically adjusts basal insulin delivery using real-time CGM data and predictive glucose levels. The twiist system is expected to be commercially available in the second quarter of 2025.

Availability

The integrated Eversense 365 and twiist™ system is anticipated to be available to users in the third quarter of 2025, marking a significant milestone in offering more personalized and convenient diabetes management solutions.

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Continuous Glucose Monitoring (CGM), Diabetes Management

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

Digital Health Funding Q3 2025: Choppy Undercurrents Beneath a Steady Surface

Most-Read

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Qualtrics Acquires Press Ganey Forsta for $6.75B to Create the Most Comprehensive AI Experience Platform

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

Pfizer and Trump Administration Announce Landmark Agreement to Lower Drug Costs

KLAS Report: Epic's Native Ambient Speech Tool Reshapes Customer AI Strategies

KLAS Report: Epic’s Native Ambient Speech Tool Reshapes Customer AI Strategies

Epic Unveils MyChart Central and New APIs to Advance Interoperability at Open@Epic

Epic Outlines Roadmap for Next-Generation Data Sharing at Open@Epic

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

Epic Launches Comet: A New AI Platform to Predict Patient Health Journeys

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

RevSpring to Acquire Kyruus Health, Creating a Unified Patient Experience

Oracle Confirms Layoffs in Kansas City

Oracle Confirms Layoffs in Kansas City

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Philips Future Health Index 2025: AI and Digital Tech Can Help Solve Cardiac Care Crisis

Optain Health Secures $26M to Advance AI-Powered Retinal Screening

Optain Health Secures $26M for AI-Powered Retinal Screening

Sutter Health and Epic Launch "Sutter Sync" to Optimize Remote Chronic Care

Sutter Health and Epic Launch “Sutter Sync” to Optimize Remote Chronic Care

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |